Scienture Holdings, Inc. (SCNX) stock
Close on Nov 13, 2026Market cap $119.09MP/E –Yield –
Scienture Holdings, Inc. grew revenue 215.9% to $431.61K over fiscal 2025. At the latest close the market valued the company at $119.09M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $119.09M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.86
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $431.61K
- Net income
- -$37.95M
- EPS, diluted
- -$1.85
- Book value per share
- $1.62
- Diluted shares
- 40M
Trading
- Previous close
- $3.01
- Open
- $2.94
- Day's range
- $2.83 – $2.94
- Volume
- 4,579
- Average volume (20 days)
- 25,427
- Beta (5 years)
- 2.06
- 52-week range
- $2.64 – $18.75
- RSI (14 days)
- 31.0
- Volatility (1 year)
- 95.8%
- Relative volume
- 0.04×
- WACC
- 15.4%
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | SCNX | S&P 500 | Difference | SCNX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.5% | -3.0% | −7.5 pts | ||
| 3 months | -75.1% | -2.8% | −72.3 pts | ||
| Year to date | -77.3% | +11.5% | −88.7 pts | ||
| 1 year | -82.7% | +13.5% | −96.2 pts | ||
| 3 years | -96.3% | +77.7% | −174.0 pts | -66.7% | +21.1% |
| 5 years | -99.7% | +72.6% | −172.3 pts | -68.5% | +11.5% |
| 10 years | -99.7% | +308.2% | −407.8 pts | -43.8% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Scienture filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Update
About Scienture
Pharmaceutical Preparations
Scienture Holdings, Inc. is a clinical-stage biopharmaceutical company focused on the development of pharmaceutical products and drug-device combination therapies. The company maintains an active development pipeline comprising multiple drug candidates, including SCN-102, SCN-104, SCN-106, and SCN-107, alongside formulations such as ARBLI losartan oral potassium suspension. Through strategic transactions and licensing arrangements, it advances proprietary product programs aimed at patients and healthcare providers requiring specialized drug treatments.
Company profile, executives and historyScienture stock: common questions
What is Scienture's stock price?
SCNX closed at $2.90 on Nov 13, 2026, down 3.65% on the day. Over the past 52 weeks it traded between $2.64 and $18.75.
What is Scienture's market cap?
Scienture was worth $119.09M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is SCNX's P/E ratio?
Scienture lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.85), so it has no meaningful P/E ratio.
How much revenue does Scienture make?
Scienture reported revenue of $431.61K for fiscal 2025, up 215.9% from a year earlier.
Does Scienture pay a dividend?
No. Scienture has not paid a cash dividend over the last twelve months.
How has SCNX stock performed over the past year?
Including dividends, SCNX returned -82.7% over the past year, against +13.5% for the S&P 500.
How many SCNX shares are sold short?
0M shares were sold short at the latest FINRA report, 0.34% of the float, or 3.1 days of average trading volume.
Who are Scienture's competitors?
Companies most similar to Scienture by business, industry and size include XTLB, LIPO, CANF, XCUR, MREO.
See a number that looks wrong?